Swedish Orphan Biovitrum Ab · OMXSTO:SOBI
Swedish Orphan Biovitrum Ab — JP Morgan Healthcare Conference 2014
23 slides from Swedish Orphan Biovitrum Ab's conference presentation, January 2014
Slide 1: Sobi: Update and Perspective
Sobi: Update and Perspective Geoffrey McDonough President and CEO JP Morgan Healthcare Conference │ San Francisco │ January 2014
Slide 2: Forward Looking Statements
Forward Looking Statements In order to utilize the ‘Safe Harbor’ provisions of the United States Private Securities Litigation Reform Act of 1995, Swedish Orphan Biovitrum is providing the following cautionary statement. This presentation contains forward-looking statements with respect to the finan
Slide 3: An International Specialty Healthcare Company Dedicated to Rare Diseases
An International Specialty Healthcare Company Dedicated to Rare Diseases 3
Slide 4: Quick Facts
Quick Facts Market Cap: $3.0 Billion USD (SEK 19.3 Billion) International Presence Share: SEK 72.80 (36.80 – 73.20) • 500+ employees • Sales and marketing organization which covers about Listing: NASDAQ OMX (STO:SOBI) 20 countries in Europe Outstanding shares: 270.4 M • Growing organizations in US,
Slide 5: A Diverse, Growing Business Platform
A Diverse, Growing Business Platform Early Stage Development Programmes Medium term investments to support commercialisation of Haemophilia Neonatology the late stage Pipeline Continued focus on growth Inflammation Genetics in key Therapeutic Areas An integrated solution for Partner Products commerci
Slide 6: A Balanced Approach to Risk + Allocation of Capital
3 A Balanced Approach to Risk + Allocation of Capital Pipeline Projects LCM with Higher investments Approved Higher earnings Products Higher risk Long-term IRR Risk Lower investments Medium earnings Year Lower risk 2013 2014 2015 2016 2017 2018 Near-term IRR Size of circle = expected revenues 6
Slide 7: R&D Pipeline 2013
R&D Pipeline 2013 Indication Project Partner Pre-Clin. Phase I Phase II Phase III Launch CAPS Kineret Hemophilia A rFVIIIFc Hemophilia B rFIXFc Improve growth in Kiobrina preterm infants Oral Mucositis in Head Kepivance & Neck Cancer Hereditary Hereditary Tyrosinemia Orfadin Liquid Tyrosinemia Type
Slide 8: Two Years Ago at JP Morgan
Two Years Ago at JP Morgan Actions to Reach Our Goals We intend to earn our way into our future based on operational performance. 1. Revenue growth through focus on key products 2. Ongoing cost discipline 3. Gross Margin improvement > Improving cash flow from operations and working capital
Slide 9: Year End Revenue + GM Expectations 2013
Year End Revenue + GM Expectations* 2013 * Based on guidance 2013 350 70 300 - 330 300 289 291 60 250 50 GM 57%-59% 200 40 GM 56% GM 52% M USD 150 30 100 20 15 50 10 0 0 -3 2011 2012 LE 2013 -50 -10 Total revenues Gross profit EBITA before non-recurring items 9
Slide 10: Net Debt Evolution
Net Debt Evolution 100 20% 90 18% 80 16% 70 14% 60 12% 50 10% 40 8% 30 6% 20 4% 10 2% 0 0% 2011 H1 2011 H2 2012 H1 2012 H2 2013 H1 2013 H2 Net Debt (MUSD) Net Debt / Equity (MUSD) 10
Slide 11: Consolidated Results Q3
Consolidated Results Q3 Financial Highlights Q3 • Total Revenues: USD 80.4 M • Year over Year increase of 12% • Year to Date increase of 8% USD M • Gross Margin: 59% • YTD Gross Margin: 59% • EBITA before non-recurring items: USD 7.3 M (4.6) • Cash Flow from operating activities: USD 3.8 M (-4) • Ca
Slide 12: YTD Q3 2013 Revenue by Business Line
YTD Q32013 Revenue by Business Line Early Stage Development Programmes Haemophilia Neonatology +13% Inflammation Genetics +5% USD 61.9 M USD 52.7 M Partner Products +20% USD 58 M ReFacto AF® USD 70.9 M +1% US$ 1 = SEK 6.43 (Exchange rate September 30, 2013) 12
Slide 13: Key Events and Drivers 2013
Key Events and Drivers 2013 Early Stage Development Programmes Haemophilia Neonatology US Kineret Growth Geographic Growth CAPS Launch EU Hyperion Middle East Full rights Kineret Inflammation Genetics H+N Data Kepivance Auxilium Partner Products Exelixis Valeant/PharmaSwiss Significant ReFacto AF® pr
Slide 14: The Share – Past Two Years
The Share – Past Two Years SEK 72.80 14
Slide 15: Strategic Priorities
Strategic Priorities 1. Near-term focus on growth in key therapeutic areas, with sustainable positive cash flow from operations. 2. Medium-term investments to ensure successful commercialization of our late-stage pipeline. 3. Long-term growth will come organically and through acquisitions in key the
Slide 16: Momentum Across Business Lines Through Q3 2013
Momentum Across Business Lines Through Q3 2013 Inflammation Inflammation Genetics Genetics& Metabolism Inflammation Inflammation Genetics&& Genetics Metabolism &Metabolism Metabolism Inflammation 30 3030 30 Genetics & Metabolism 30 3030 30 • 25 2525 25 US Volume + Price • 25 2525 25 Growth in Middle
Slide 17: Strategic Priorities – 2014: A Pivotal Year
Strategic Priorities – 2014: A Pivotal Year 1. Near-term focus on growth in key therapeutic areas, with sustainable positive cash flow from operations. 2. Medium-term investments to ensure successful commercialization of our late-stage pipeline. 3. Long-term growth will come organically and through
Slide 18: Hemophilia – Long-Lasting Factor Programs
Hemophilia – Long-Lasting Factor Programs A $3.7B Market in Sobi Territory Today Key Milestones • rFIXFc US Launch est. Q2 2014 • KIDS B-LONG study on-going • rFVIIIFc US Launch est. MY 2014 • KIDS A-LONG study on-going • Sobi expects to opt-in on rFVIIIFc in 2H2014 18
Slide 19: Updates from ASH December 2013 and ISTH July 2013
Updates from ASH December 2013 and ISTH July 2013 Kids B-LONG poster presented by Biogen Idec1 Kids A-LONG poster presented by Biogen Idec2 at ASH at ASH • Compared with currently available FIX products, • Compared with currently available FVIII products, rFIXFc had an extended half-life (>3-fold in
Slide 20: Neonatology – Kiobrina (rh-BSSL)
Neonatology – Kiobrina (rh-BSSL) Key Milestones • Kiobrina EU topline phase 3 data 1Q 2014 • Kiobrina US phase 3 FPI 1H 2014 20
Slide 21: Top Line Results Q1 2014: Growth, Safety, Hospital Outcomes
Top Line Results Q1 2014: Growth, Safety, Hospital Outcomes Phase III study Growth Hospital Safety + Neurodevelopment 1yr Neurodevelopment 2yrs IQ 4 wks 3 mo 12 mo 24mo 8 yrs Growth velocity Readiness for hospital discharge Head circumference Safety Top line results Safety Tolerability Q1 2014 Toler
Slide 22: Planned Key Events 2014 -- 2016
Planned Key Events* 2014 -- 2016 Sobi’s Key Milestones Kineret Orfadin Kepivance Factor VIII Factor IX Kiobrina SOBI002 NOMID approval US Filling of liquid Phase I Phase I Phase I Phase I 1 Phase I formulation in US NOMID launch US and EU Phase II Phase II Phase II Phase II CAPS approval EU 1 Assume
Slide 23: Strategic Priorities
Strategic Priorities 1. Near-term focus on growth in key therapeutic areas, with sustainable positive cash flow from operations. 2. Medium-term investments to ensure successful commercialization of our late-stage pipeline. 3. Long-term growth will come organically and through acquisitions in key the
Swedish Orphan Biovitrum (Sobi) — JP Morgan Healthcare Conference 2014 on 6ix